Abstract

Atopic dermatitis in children: A summary of therapeutic recommendations, the role of skin care, and impact on the quality of life

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that most often manifests itself in early childhood. It frequently coexists with other atopic conditions such as bronchial asthma or allergic rhinitis. The characteristic symptoms include persistent pruritus, dry skin, and inflammatory lesions with varied localization and morphology depending on the patient’s age. The diagnosis of AD is established based on a detailed medical history and physical examination. Treatment primarily involves appropriate skin care using mild soap substitutes and emollients, avoiding exacerbating factors, as well as using topical and systemic medications. This paper discusses the impact of AD on the quality of life of patients and their families, summarizes the current therapeutic strategies, and emphasizes the importance of patient and caregiver education for an effective disease management.

Piśmiennictwo

1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet Lond Engl 2020;396(10247):345-60. doi: 10.1016/S0140-6736(20)31286-1

2. Weidinger S, Simpson EL, Silverberg JI, et al. Burden of atopic dermatitis in paediatric patients: an international cross-sectional study. Br J Dermatol 2024;190(6):846-57. doi: 10.1093/bjd/ljad449

3. Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab 2015;66(Suppl. 1):8-16. doi: 10.1159/000370220

4. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc 2019;40(2):84-92. doi: 10.2500/aap.2019.40.4202

5. Moosbrugger-Martinz V, Leprince C, Méchin MC, et al. Revisiting the Roles of Filaggrin in Atopic Dermatitis. Int J Mol Sci 2022;23(10):5318. doi: 10.3390/ijms23105318

6. Makowska K, Nowaczyk J, Blicharz L, et al. Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments. Int J Mol Sci 2023;24(1):781. doi: 10.3390/ijms24010781

7. Han H, Roan F, Ziegler SF. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol Rev 2017;278(1):116-30. doi: 10.1111/imr.12546

8. Koh LF, Ong RY, Common JE. Skin microbiome of atopic dermatitis. Allergol Int 2022;71(1):31-9. doi: 10.1016/j.alit.2021.11.001

9. Blicharz L, Rudnicka L, Samochocki Z. Staphylococcus aureus: an underestimated factorin the pathogenesis of atopic dermatitis? Adv Dermatol Allergol 2019;36(1):11-17. doi: 10.5114/ada.2019.82821

10. Biagini Myers JM, Khurana Hershey GK. Eczema in early life: genetics, the skin barrier, and lessons learned from birth cohort studies. J Pediatr 2010;157(5):704-14. doi: 10.1016/j.jpeds.2010.07.009

11. Odhiambo JA, Williams HC, Clayton TO, et al. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009;124(6): 1251-1258.e23. doi: 10.1016/j.jaci.2009.10.009

12. Sybilski AJ, Raciborski F, Lipiec A, et al. Atopic dermatitis is a serious health problem in Poland. Epidemiology studies based on the ECAP study. Postepy Dermatol Alergol 2015;32(1):1-10. doi: 10.5114/pdia.2014.40935

13. Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primer 2018;4(1):1. doi: 10.1038/s41572-018-0001-z

14. Ahn C, Huang W. Clinical Presentation of Atopic Dermatitis. In: Fortson EA, Feldman SR, Strowd LC (eds.). Management of Atopic Dermatitis. Vol 1027. Advances in Experimental Medicine and Biology. Springer International Publishing, 2017:39-46. doi: 10.1007/978-3-319-64804-0_4

15. Hanifin JM, Rajka G. Diagnostic Features of Atopic Dermatitis. Acta Derm Venereol 1980;60:44-7. doi: 10.2340/00015555924447

16. Christensen MO, Barakji YA, Loft N, et al. Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge‐proven food allergy: A systematic review and meta‐analysis. J Eur Acad Dermatol Venereol 2023;37(5):984-1003. doi: 10.1111/jdv.18919

17. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol 2022;36(11):1904-26. doi: 10.1111/jdv.18429

18. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol 2024;90(2):e43-e56. doi: 10.1016/j.jaad.2023.08.102

19. Nowicki R, Trzeciak M, Kaczmarski M, et al. Atopic dermatitis. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allergology, Polish Pediatric Society and Polish Society of Family Medicine. Part I. Prophylaxis, topical treatment and phototherapy. Dermatol Rev 2019;106(4):354-74. doi: 10.5114/dr.2019.88253

20. Kunz B, Oranje AP, Labrèze L, et al. Clinical Validation and Guidelines for the SCORAD Index: Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195(1):10-19. doi: 10.1159/000245677

21. Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001;10(1):11-18. doi: 10.1034/j.1600-0625.2001.100102.x

22. Lax SJ, Harvey J, Axon E, et al. Strategies for using topical corticosteroids in children and adults with eczema. Cochrane Skin Group, ed. Cochrane Database Syst Rev 2022;2022(3). doi: 10.1002/14651858.CD013356.pub2

23. Carr WW. Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations. Pediatr Drugs 2013;15(4):303-10. doi: 10.1007/s40272-013-0013-9

24. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. J Eur Acad Dermatol Venereol 2022;36(9):1409-31. doi: 10.1111/jdv.18345

25. Gooderham MJ, Hong HC Ho, Eshtiaghi P, et al. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 2018;78(3):S28-S36. doi: 10.1016/j.jaad.2017.12.022

26. Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019;143(1):155-72. doi: 10.1016/j.jaci.2018.08.022

27. Navarro-Triviño FJ, Salazar-Nievas M, Sanz-Cabanillas JL, et al. Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients. Australas J Dermatol. Published online April 8, 2024:ajd.14264. doi: 10.1111/ajd.14264

28. Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol 2021;148(4):927-40. doi: 10.1016/j.jaci.2021.08.009

29. Hong J, Buddenkotte J, Berger TG, et al. Management of itch in atopic dermatitis. Semin Cutan Med Surg 2011;30(2):71-86. doi: 10.1016/j.sder.2011.05.002

30. Silverberg JI, Wollenberg A, Reich A, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. The Lancet 2024;404(10451):445-60. doi: 10.1016/S0140-6736(24)01203-0

31. Sun D, Ong PY. Infectious Complications in Atopic Dermatitis. Immunol Allergy Clin North Am 2017;37(1):75-93. doi: 10.1016/j.iac.2016.08.015

32. Hill SE, Yung A, Rademaker M. Prevalence of Staphylococcus aureus and antibiotic resistance in children with atopic dermatitis: A New Zealand experience: S. aureus resistance in NZ children. Australas J Dermatol 2011;52(1):27-31. doi: 10.1111/j.1440-0960.2010.00714.x

33. Bakaa L, Pernica JM, Couban RJ, et al. Bleach baths for atopic dermatitis. Ann Allergy Asthma Immunol 2022;128(6):660-668.e9. doi: 10.1016/j.anai.2022.03.024

34. Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 2013;131(2):428-33. doi: 10.1016/j.jaci.2012.10.041

35. Hon KL, Kung JSC, Ng WGG, et al. Emollient treatment of atopic dermatitis: latest evidence and clinical considerations. Drugs Context 2018;7:212530. doi: 10.7573/dic.212530

36. Harcharik S, Emer J. Steroid-sparing properties of emollients in dermatology. Skin Ther Lett 2014;19(1):5-10

37. Tiplica GS, Kaszuba A, Malinauskienė L, et al. Prevention of Flares in Children with Atopic Dermatitis with Regular Use of an Emollient Containing Glycerol and Paraffin: A Randomized Controlled Study. Pediatr Dermatol 2017;34(3):282-9. doi: 10.1111/pde.13113

38. Zhong Y, Samuel M, van Bever H, et al. Emollients in infancy to prevent atopic dermatitis: A systematic review and meta-analysis. Allergy 2022;77(6):1685-99. doi: 10.1111/all.15116

39. Bawany F, Northcott CA, Beck LA, et al. Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies. J Allergy Clin Immunol Pract 2021;9(4):1488-500. doi: 10.1016/j.jaip.2020.12.007

40. Chernyshov P. Stigmatization and self-perception in children with atopic dermatitis. Clin Cosmet Investig Dermatol 2016;9:159-66. doi: 10.2147/CCID.S91263

41. Neri I, Galli E, Baiardini I, et al. Implications of Atopic Dermatitis on the Quality of Life of 6-11 Years Old Children and Caregivers (PEDI-BURDEN). J Asthma Allergy 2023;16:383-96. doi: 10.2147/JAA.S404350

42. Kobusiewicz A, Zalewska-Janowska A. The burden of atopic dermatitis: its impact on family psychosocial functioning. Dermatol Rev 2023;110(4):518-28. doi: 10.5114/dr.2023.128635

43. Ali F, Vyas J, Finlay AY. Counting the Burden: Atopic Dermatitis and Health-related Quality of Life. Acta Derm Venereol 2020;100(12):adv00161. doi: 10.2340/00015555-3511

44. Chung J, Simpson EL. The socioeconomics of atopic dermatitis. Ann Allergy Asthma Immunol 2019;122(4):360-6. doi: 10.1016/j.anai.2018.12.017

Do góry